LOS ANGELES, CA / ACCESSWIRE / December 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto ...

Firefly Neuroscience, Inc. has entered into a securities purchase agreement with Helena Special Opportunities LLC, raising up to $2.4 million through a private placement of a convertible ...

Two new neuroscience studies offer fascinating answers ... The opinions expressed here by Inc.com columnists are their own, not those of Inc.com.

Analyst Price Forecast Suggests 172.98% Upside As of December 3, 2024, the average one-year price target for Alto Neuroscience is $10.46/share. The forecasts range from a low of $4.04 to a high of ...

JonesTrading analyst Justin Walsh initiated coverage with a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report) today and set a price target of $18.00. The company’s shares closed ...

A Herndon man charged with killing his wife and another man last year, then trying to make it look like he interrupted a home invasion, was indicted Monday by a Fairfax County grand jury on ...

announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The ...

Credit: Neuroscience News Uma Karmarkar’s research examines the factors that consciously and unconsciously influence how people make decisions, including purchases and what that means for markets. The ...

Vigil Neuroscience, Inc. has a 12-month low of $1.99 and a 12-month high of $6.06. The stock has a fifty day moving average of $3.24 and a 200-day moving average of $3.56.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia ...